Oncolytics Biotech has completed patient enrollment in a randomized, phase II study of paclitaxel plus reolysin versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
The trial is sponsored by the U.S. National Cancer Institute (NCI) through a Clinical Trials Agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI and Oncolytics.
"Our randomized clinical program continues to gather momentum as this is the second randomized study sponsored by the NCI that has completed enrollment in the last quarter," said Dr. Brad Thompson, president and CEO of Oncolytics. "Ovarian cancer is often diagnosed at a very late stage, requiring more aggressive interventions and resulting in relatively low five-year survival rates."
The current study is a randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel with reolysin in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer. Patients were randomized to receive either paclitaxel alone or paclitaxel plus reolysin.
Patients in both arms received treatment with paclitaxel, with the second arm also receiving intravenous reolysin. Patients received standard doses of paclitaxel on days one, eight and 15 every 28 days. In the second arm, patients received, on days one through five of each 28-day cycle, intravenous reolysin at a dose of 3x10(10) TCID(50).
The primary objectives of the trial are to estimate the progression-free survival hazard ratio of the combination of weekly paclitaxel with reolysin to weekly paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer and to determine the frequency and severity of adverse events associated with treatment with weekly paclitaxel alone and weekly paclitaxel with reolysin as assessed by Common Terminology Criteria for Adverse Events (CTCAE).
The secondary objectives are to estimate the progression-free survival and overall survival of patients treated with weekly paclitaxel alone and weekly paclitaxel with reolysin; to estimate (and compare) the proportion of patients who respond to the regimen on each arm of the study (according to RECIST 1.1 with measurable patients and by CA-125 for those patients with detectible disease only); and to characterize and compare progression-free survival and overall survival in patients with measurable disease (RECIST 1.1 criteria) and patients with detectable (nonmeasurable) disease.
